Selective androgen receptor modulators in drug discovery: Medicinal chemistry and therapeutic potential

Current Topics in Medicinal Chemistry

Volumn 6, Issue 3, 2006, Pages 245-270

  Cadilla, Rodolfo P ^a   Turnbull, Philip ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

AR; Dihydrotestosterone; Estradiol; Hypogonadism; Modulation; SARMs; Testosterone; Tissue selectivity

Indexed keywords

3 (2 NITROPHENYL)THIOINDOLE DERIVATIVE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANILIDE; ANTIANDROGEN; AROMATIC AMINE; AZASTEROID; BICALUTAMIDE; BMS 564929; CARBONYLAMINOBENZIMIDAZOLE DERIVATIVE; COUMARIN DERIVATIVE; ESTRADIOL; FINASTERIDE; FLUTAMIDE; HORMONE RECEPTOR AFFECTING AGENT; HYDANTOIN DERIVATIVE; HYDROXYFLUTAMIDE; LGD 121071; MALE CONTRACEPTIVE AGENT; METHYLTESTOSTERONE; NILUTAMIDE; PROPIONAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; RU 59063; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SUCCINIMIDE DERIVATIVE; TESTOSTERONE DERIVATIVE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN DEFICIENCY; ANDROPAUSE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG DEGRADATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; GYNECOMASTIA; HEMATOCRIT; HUMAN; HYPOGONADISM; LIVER TOXICITY; MALE; MUSCLE ATROPHY; NONHUMAN; OSTEOPOROSIS; POLYCYTHEMIA; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REGULATORY MECHANISM; REVIEW; SEXUAL DYSFUNCTION; SLEEP APNEA SYNDROME;

ANDROGEN ANTAGONISTS; ANIMALS; DRUG DESIGN; HUMANS; RECEPTORS, ANDROGEN;

EID: 33646156657     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776173456     Document Type: Review

References (157)

1. Chang, C. Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical Applications. 2002, 503 pp. Publisher: (Kluwer Academic Publishers, Norwell, Mass).
2. Gao, W.; Bohl, C. E.; Dalton, J. T. Chemistry and Structural Biology of Androgen Receptor. Chem. Rev. ACS ASAP.
3. Chen, J.; Kim, J.; Dalton, J. T. Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Mol. Intervent 2005, 5, 173-188.
4. Buijsman, R. C.; Hermkens, P. H. H.; van Rijn, R. D.; Stock, H. T.; Teerhuis, N. M. Non-Steroidal Steroid Receptor Modulators. Curr. Med. Chem. 2005, 12, 1017-1075.
5. Chengalvala, M.; Oh, T.; Roy, A. K. Selective Androgen Receptor Modulators. Exp. Op. Ther. Pat. 2003, 13, 59-66.
6. Chen, F.; Rodan, G. A.; Schmidt, A. Development of Selective Androgen Receptor Modulators and their Therapeutic Applications. Zhonghua Nankexue 2002, 8, 162-168.
7. Zhi, L.; Martinborough, E. Selective Androgen Receptor Modulators. Ann. Rep. Med Chem. 2001, 36, 169-180
8. Lin, X.; Huebner, V. Non-steroidal Ligands for Steroid Hormone Receptors. Curr. Opin. Drug Disc. Dev. 2000, 3, 383-398.
9. Singh, S. M.; Gauthier, S.; Labrie, F. Androgen Receptor Antagonists (Antiandrogens): Structure-Activity Relationships. Curr. Med Chem. 2000, 7, 211-247.
10. Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily. Science 1988, 240, 889-95.
11. Beato M. Gene Regulation by Steroid Hormones. Cell 1989, 56, 335-44.
12. Cato, A. C. B. and Peterziel, H. The Androgen Receptor as Mediator of Gene Expression and Signal Transduction Pathways. TEM 1998, 9, 150-154.
13. 2-Terminal and Steroid-Binding Domains. J. Biol. Chem. 1993, 268, 19004-12.
14. Schoenmakers, E.; Alen, P.; Verrijdt, G.; Peeters, B.; Verhoeven, G.; Rombauts, W.; Claessens, F. Differential DNA Binding by the Androgen and Glucocorticoid Receptors Involves the Second Zn-Finger and a C-Terminal Extension of the DNA-Binding Domains. Biochem. J. 1999, 341, 515-21.
15. Georget; V.; Lobaccaro, J. M.; Terouanne, B.; Mangeat, P.; Nicolas, J. C.; Sultan, C. Trafficking of the Androgen Receptor in Living Cells with Fused Green Fluorescent Protein-Androgen Receptor. Mol. Cell. Endo. 1997, 129, 17-26.
16. Wang, L.; Hsu, C.-L.; Chang, C. Androgen Receptor Compressors: an Overview. Prostate 2005, 63, 117-130.
17. 2- and COOH-Terminal Interactions Result in the Differential Influences on the AR-Mediated Transactivation and Cell Growth. Mol. Endo. 2005, 19, 350-361.
18. Smith, C. L.; O'Malley, B. W. Coregulator Function: a Key to Understanding Tissue Specificity of Selective Receptor Modulators. Endoc. Rev. 2004, 25, 45-71.
19. Heinlein, C. A. and Chang, C. The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions. Mol. Endo. 2002, 16, 2181-2187.
20. Kousteni, S.; Chen, J.-R.; Bellido, T.; Han, L.; Ali, A. A.; O'Brien, C. A.; Plotkin, L.; Fu, Q.; Mancino, A. T.; Wen, Y.; Vertino, A. M.; Powers, C. C.; Stewart, S. A.; Ebert, R.; Parfitt, A. M.; Weinstein, R. S.; Jilka, R. L.; Manolagas, S. C. Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids. Science 2002, 298, 843-846.
21. Kousteni, S.; Bellido, T.; Plotkin, L. I.; O'Brien, C. A.; Bodenner, D. L.; Han, L.; Han, K.; DiGregorio, G. B.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Roberson, P. K.; Weinstein, R. S.; Jilka, R. L.; Manolagas, S. C. Nongenotropic, Sex-Nonspecific Signaling Through the Estrogen or Androgen Receptors: Dissociation from Transcriptional Activity. Cell 2001, 104, 719-730.
22. Morales, A. and Tenover, J. L. Urol. Clin. North Am. 2002, 29, 975.
23. Hanada, K.; Furuya, K.; Yamamoto, N.; Nejishima, H.; Ichikawa, K.; Nakamura, T.; Miyakawa, M.; Amano, S.; Sumita, Y.; Oguro, N. Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis. Biol. Pharm. Bull. 2003, 26, 1563-1569.
24. Yin D.; Gao W.; Kearbey J. D.; Xu H.; Chung K.; He Y.; Marhefka C. A; Veverka K. A.; Miller D. D.; Dalton J. T. Pharmacodynamics of Selective Androgen Receptor Modulators. J. Pharm. Exp. Ther. 2003, 304, 1334-40.
25. Tucker, H.; Crook, J. W.; Chesterson, G. J. Non-Steroidal AntiAndrogens. Synthesis and Structure-Activity Relationships of 3-Substituted Derivatives of 2-Hydroxypropionanilides. J. Med. Chem. 1988, 31, 954-9.
26. Morris J. J; Hughes L. R; Glen A. T; Taylor P. J. Non-Steroidal Antiandrogens. Design of Novel Compounds Based on an Infrared Study of the Dominant Conformation and Hydrogen-Bonding Properties of a Series of Anilide Antiandrogens. J. Med. Chem. 1991, 341, 447-55.
27. Tucker, H.; Chesterson, G. J. Resolution of the Non-steroidal Antiandrogen 4′-Cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy- 2-methyl-3′-(trifluoromethyl) propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer. J. Med. Chem. 1988, 31, 885-7.
28. Dalton J. T.; Mukherjee A.; Zhu Z.; Kirkovsky L.; Miller D. D. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Comm. 1998, 2441, 1-4.
29. Steiner, M. S.; Dalton, J. T.; Miller, D. D.; Veverka, K. A. Substituted Propanamide Selective Androgen Receptor Modulators and Methods of Use. US. Pat. Apl. 038110, Feb 17, 2005.
30. Dalton, J. T.; Miller, D. D.; Yin, D.; He, Y. Metabolites of Selective Androgen Receptor Modulators (SARMs) and Methods of Use Thereof. US. Pat. Apl. 260108, Dec 23, 2004.
31. He Y.; Yin D.; Perera M.; Kirkovsky L.; Stourman N.; Li W.; Dalton J. T; Miller D. D. Novel Nonsteroidal Ligands with High Binding Affinity and Potent Functional Activity for the Androgen Receptor. Eur. J. Med. Chem. 2002, 37, 619-34.
32. Marhefka C. A.; Gao W.; Chung K.; Kim J.; He Y.; Yin D.; Bohl C.; Dalton J. T; Miller D. D. Design, Synthesis and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators. J. Med. Chem. 2004, 47, 993-8.
33. Kearbey J. D.; Wu D.; Gao W.; Miller D. D.; Dalton J. T. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl- N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in Rats, a Non-steroidal Selective Androgen Receptor Modulator. Xenobiotica 2004, 34, 273-80.
34. Kirkovsky, L.; Mukherjee A.; Yin D.; Dalton J. T.; Miller D. D. Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogues Bearing Electrophilic Groups in the B Aromatic Ring. J. Med. Chem. 2000, 43, 581-90.
35. Dalton, J. T.; Y.; Miller, D. D.; He, Yin.; D.; Steiner, M. S.; Veverka, K. A. Multi-substituted Selective Androgen Receptor Modulators and Methods of Use Thereof. World Pat. Apl. 74449, Sept 12, 2003.
36. Kim, J.; Wu, D.; Hwang, D. J.; Miller, D. D.; Dalton, J. T. The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3- trifluoromethyl-phenyl)-propionamides is a Major Structural Determinant of in vivo Disposition and Activity of Selective Androgen Receptor Modulators. J Pharmacol. Exp. Ther. 2005, 315, 230-239.
37. Dalton, J.; Miller, D. D.; Steiner, M. S.; Veverka, K. A.; Kearby, J. Treating Bone-Related Disorders with Selective Androgen Receptor Modulators. World Pat. Apl. 37201, April 28, 2005.
38. Gao W.; Kearbey J. D.; Nair V. A.; Chung K.; Parlow A. F.; Miller D. D.; Dalton J. T. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5-Alpha-Reductase Inhibitor Finasteride and the AntiAndrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia. Endocrinology 2004, 145, 5420-8.
39. Chen, J.; Hwang, D. J.; Bohl, C. E.; Miller, D. D.; Dalton, J. T. A Selective Androgen Receptor Modulator for Hormonal Male Contraception. J. Pharmacol. Exp. Ther. 2005, 312, 546-553.
40. Dalton, J. T.; Miller, D. D.; Steiner, M. S.; Veverka, K. A.; Hwang, D. J.; Chen, J. Arylamides as Multi-substitued Selective Androgen Receptor Modulators. US. Pat. Apl. 33074, Feb 10, 2005.
41. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer. Proc. Nat. Acad. Sci. 2005, 102, 6201-6206.
42. Ng, R. A.; Sui, Z. Preparation of Thiazoline Derivatives as Selective Androgen Receptor Modulators (SARMs). World Pat. Apl. 113309, Dec 29, 2004.
43. Ratilainen, J.; Moilanen, A.; Toermaekangas, O.; Karjalainen, A.; Huhtala, P.; Wohlfahrt, G.; Kallio, P. Propionamides, in Particular N-phenyl Derivatives, Useful as Androgen Receptor Modulators. World Pat. Apl. 794, Jan 6, 2005.
44. Jones, T. K.; Goldman, M. E.; Pooley, C. L. F.; Winn, D. T.; Edwards, J. E.; West, S. J.; Tegley, C. M.; Zhi, L.; Hamann, L. G. Preparation of Quinolines and Fused Quinolines as Steroid Receptor Modulators. World Pat. Apl. 9619458, June 27, 1996.
45. Hamann, L. G.; Higuchi, R. I.; Zhi, L.; Edwards, J. P.; Wang, X.; Marschke, K. B.; Kong, J. W.; Farmer, L. J.; Jones, T. K. Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines. J. Med. Chem. 1998, 41, 623-639.
46. Zhi, L.; Tegley, C. M.; Marschke, K. B.; Jones, T. K. Switching Androgen Receptor Antagonists to Agonists by Modifying C-ring Substituents on Piperidino[3,2-g]quinolinone. Biorg. Med. Chem. Lett. 1999, 9, 1009-12.
47. Higuchi R. I; Edwards J. P.; Caferro T. R.; Ringgenberg J. D.; Kong J. W.; Hamann, L. G.; Arienti, K. L.; Marschke, K. B.; Davis, R. L.; Farmer, L. J.; Jones, T. K. 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: Potent, Non-steroidal Androgen Receptor Agonists. Biorg. Med. Chem. Lett. 1999, 9, 1335-40.
48. Hamann, L. G.; Mani, N. S.; Davis, R. L.; Wang, X. N.; Marschke K.B.; Jones, T. K. Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem. 1999, 42, 210-2.
49. Edwards, J. P.; West S. J.; Pooley, C. L.; Marschke, K. B.; Farmer, L. J.; Jones, T. K. New Nonsteroidal Androgen Receptor Modulators Based on 4-(trifluoromethyl)-2(1H-pyrrolidino[3,2-g] Quinolinone. Biorg. Med. Chem. Lett. 1998, 8, 745-50.
50. Higuchi, R.; Arienti, K. L.; Neelakandha, M.; Pio, B.; Zhi, L.; Chen,P.; Caferro, T. R. Preparation of Androgen Receptor Ligands. World Pat. Apl. 16139, March 8, 2001.
51. Zhi, L.; Tegley, C.; Pio, B.; Van Oeveren, C. A.; Motamedi, M.; Martinborough, E.; West S.; Higuchi, R.; Hamann, L.; Farmer, L. Preparation of Quinolinones and Related Bicyclic Compounds as Androgen and Progesterone Receptor Modulators. World Pat. Apl. 16108, March, 8, 2001.
52. Rosen, J.; Negro-Vilar, A. Novel, Non-steroidal, Selective Androgen Receptor Modulators (SARMs) with Anabolic Activity in Bone and Muscle and Improved Safety Profile. J. Musc. Neur. Interact. 2002, 2, 222-4.
53. Zhi, L.; Van Oeveren, C. A.; Chen, J.; Higuchi, R. I. Preparation of Pyrroloquinolines, Pyridoquinolines, Pyranoquinolines and Related Tricyclic Compounds as Androgen Receptor Modulators. World Pat. Apl. 66475, Aug 29, 2002.
54. Higuchi, R. I.; Zhi, L.; Karanewsky, D. S.; Thompson, A. W.; Caferro, T. R.; Mani, N. S.; Chen, J.; Cummings, M. L.; Edwards, J. P.; Adams, M. E.; Deckhut, C. L. F. Preparation of Tricyclic Quinolinone Androgen Receptor Modulator Compounds. World Pat. Apl. 68427, Sept 6, 2002.
55. Edwards, J. P.; Higuchi R. L; Winn, D. T.; Pooley, C. L.; Caferro, T. R.; Hamann, L. G.; Zhi, L.; Marschke, K. B.; Goldman, M. E.; Jones, T. K. Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H-pyrano[3,2-glquinolin-2-one. Biorg. Med. Chem. Lett. 1999, 9, 1003-8.
56. Jones, T. K.; Goldman, M. E.; Pooley, C. L. F.; Winn, D. T.; Edwards, J. E.; West, S. J.; Tegley, C. M.; Zhi, L.; Hamann, L. G.; et al. Preparation of Quinolines and Fused Quinolines as Steroid Receptor Modulators. World Pat. Apl. 9619458, June 27, 1996.
57. Kong, J, W.; Hamann, L. G.; Ruppar, D. A.; Edwards, J. P.; Marschke, K. B.; Jones, T. K. Effects of Isosteric Pyridone Replacements in Androgen Receptor Antagonists Based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl -8-pyridono[5,6-g]quinolines. Biorg. Med. Chem. Lett. 2000, 10, 411-414.
58. Hamann, L. G.; Kong, J.; Edwards, J. P. Preparation and Formulationof 6-trifluoromethyl-9-pyrido[3,2-g]quinolines as Androgen Receptor Ligands. World Pat. Apl. 16133, March 8, 2001.
59. Zhi, L.; Martinborough, E.; Shen, Y.; Stevens L., Thomas L.; Wu, M.; Long, Y. O. Preparation of 6-pyrrolidinyl- and 6-piperidinylquinolinones as Androgen Receptor Modulators. World Pat Apl. 18573, March 3, 2005.
60. Gant, T. G. Preparation of (-)-5-ethyl-4-trifluoromethyl-5,6,7, 8-tetrahydro-l-oxa-8-azaanthracen-2-one as an Androgen Mediator. Eur. Pat. Apl. 1002799, May 24, 2000.
61. Miyagawa, M.; Sumida, Y.; Nejishima, H.; Yamamoto, N. Preparation of Carboxyaminocoumarins as Androgen Receptor Agonists and Antagonists. Jap. Pat. Apl. 73374, March 12, 2003.
62. Coleman, P.J.; Neilson, L. A. Preparation of Chromenoazepinones and Azepinoquinolinones as Androgen Receptor Modulators. World Pat. Apl. 34987, May 1, 2003.
63. Lanter, J. C.; Sui, Z.; Fiordeliso, J. J. Preparation of 2-oxoquinolinyl-fused Heterocycles as Androgen Receptor Modulators. World Pat. Apl. 90672, Nov 6, 2003.
64. Ruda, M.; Wensbo, D. Preparation of Benzo[f]quinolinecarboxylates as Nuclear Hormone Receptor Modulators. World Pat. Apl. 37792, May 6, 2004.
65. Van Dort, M. E.; Robins, D. M.; Wayburn, B. Design, Synthesis, and Pharmacological Characterization of 4-[4,4-Dimethyl-3-(4-hydroxybutyl)-5-oxo-2 -thioxo-l-imidazolidinyl]-2-iodobenzonitrile as a High-Affinity Nonsteroidal Androgen Receptor Ligand. J. Med. Chem. 2000, 43, 3344-3347.
66. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R. Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic Structures of the Ligand-binding Domains of the Androgen Receptor and its T877A Mutant Complexed with the Natural Agonist Dihydrotestosterone. Proc. Nat. Acad. Sci. 2001, 98, 4904-9.
67. Balog, A.; Salvati, M. E; Shan, W.; Mathur, A.; Leith, L. W.; Wei, D. D.; Attar, R. M.; Geng, J.; Rizzo, C. A.; Wang, C.; Krystek, S. R.; Tokarski, J. S.; Hunt, J. T.; Gottardis, M.; Weinmann, R. The Synthesis and Evaluation of [2.2.1]-bicycloazahydantoins as Androgen Receptor Antagonists. Biorg. Med. Chem. Lett. 2004, 14, 6107-11.
68. Salvati, M. E.; Gottardis, M. M.; Krystek, S. R. Jr.; Attar, R. M.; Sack, J. S. Synthesis of Selective Androgen Receptor Modulators and Methods for their Identification, Design and Use. World Pat. Apl. 617, Jan 3, 2002.
69. Salvati, M. E.; Balog, J. Aaron; Shan, W.; Giese, S. Preparation of Methanoimidazopyridinones, Methanoimidazopyrazinones, Related Compounds as Modulators of Nuclear Hormone Receptor Function. World Pat. Apl. 653, Jan 3, 2002.
70. Salvati, M. E.; Balog, J. A.; Pickering, D. A.; Giese, S.; Furs, A.; Li, We.; Patel, R. N.; Hanson, R. L. Preparation of Fused Heterocyclic Succinimides as Modulators of Nuclear Hormone Receptor Function. World Pat. Apl. 24702, March, 28, 2002.
71. Salvati, M. E.; Attar, R. M.; Gottardis, M. M.; Balog, J. A.; Pickering, D. A.; Martinez, R. L.; Sun, C. Preparation of Fused Cyclic Succinimide Compounds and Analogs Thereof, as Modulators of Nuclear Hormone Receptor Function. World Pat. Apl. 67939, Sep 6, 2002.
72. Sun, C.; Robl, J. A.; Salvati, M. E.; Wang, T.; Hamann, L.; Augeri, D. Preparation of Imidazole-containing Heterobicyclic Modulators of Androgen Receptor Function. World Pat. Apl. 11824, Feb 13, 2003.
73. Salvati, M. E.; Balog, J. A.; Pickering, D. A.; Zhu, H. Preparation of Fused Heterocyclic Compounds and Analogs Thereof as Modulators of Nuclear Hormone Receptor Function. World Pat. Apl. 53358, July 3, 2003.
74. Salvati, M. E.; Balog, J. A.; Pickering, D. A.; Giese, S.; Fura, A.; Li, W.; Patel, R. N.; Hanson, R. L.; Mitt, T.; Roberge, J.; Corte, J.R.; Spergel, S. H.; Rampulla, R. A.; Misra, R.; Xiao, H. Preparation of Fused Succinimides as Modulators of Nuclear Hormone Receptor Function. World Pat. Apl. 62241, July 31, 2003.
75. Sun, C.; Hamann, L.; Augeri, D.; Bi, Y.; Robl, J.; Huang, Y.; Wang, T.; Simpkins, L.; Holubec, A. Preparation of Pyrrolo[1,2-c]imidazoles as Bicyclic Modulators of Androgen Receptor Function. World Pat. Apl. 96980, Nov 27, 2003.
76. Salvati, M. E.; Balog, J. A.; Shan, W.; Giese, S.; Harikrishnan, L. S. Preparation of Methanoimidazopyridinones, Methanoimidazopyrazinones, and Related Compounds as Modulators of Nuclear Hormone Receptor Function. US. Pat. Apl. 77606, May 22, 2004.
77. Sun, C. 29th National Medicinal Chemistry Symposium, Madison, WI, US, June 27-July 1, 2004.
78. Sun, C.; Hamann, L.; Augeri, D.; Bi, Y.; Robl, J.; Huang, Y.; Wang, T.; Holubec, A.; Simpkins, L.; Sutton, J. C.; Li, J. J. Preparation of Bicyclic Compounds as Modulators of Androgen Receptor Function. US. Pat. Apl. 181064, Sept 16, 2004.
79. Hamann, L. G.; Augeri, D. J.; Manfredi, M. C. Open Chain Prolyl Urea-related Modulators of Androgen Receptor Function Therapeutic Use for Nuclear Hormone Receptor-Associated Conditions. World Pat. Apl. 45518, June 3, 2004.
80. Bi, Y.; Hamann, L. G.; Manfredi, M. C.; Simpkins, L M. Monocyclic N-aryl Hydantoins as Modulators of Androgen Receptor Function, their Preparation and Pharmaceutical Compositions. World Pat. Apl. 49580, June 2, 2005.
81. Salvati M. E.; Balog A.; Wei D. D.; Pickering D.; Attar R. M.; Geng J.; Rizzo C. A; Hunt J. T.; Gottardis M. M.; Weinmann R.; Martinez R. Identification of a Novel Class of Androgen Receptor Antagonists Based on the Bicyclic-1H-isoindole-1,3(2H)-dione Nucleus. Biorg. Med. Chem. Lett. 2005, 15, 389-93.
82. Salvati M. E.; Balog A.; Shan W.; Wei D. D; Pickering D.; Attar R. M; Geng J.; Rizzo C. A.; Gottardis M. M.; Weinmann R.; Krystek S. R.; Sack J.; An Y.; Kish K. Structure Based Approach to the Design of Bicyclic-1H-isoindole-1,3(2H)-dione Based Androgen Receptor Antagonists. Biorg. Med. Chem. Lett. 2005, 15, 271-6.
83. Hanada, K.; Furuya, K.; Inoguchi, K.; Miyakawa, M.; Nagata, N. Preparation of Tetrahydroquinoline Derivatives as Androgen Receptor Regulators. World Pat. Apl. 27086, April 19, 2001.
84. Miyakawa, M.; Amano, S.; Kamei, M.; Hanada, K.; Furuya, K.; Yamamoto, N. Preparation of Tetrahydroquinoline Derivatives as Androgen Agonists or Antagonists. World Pat. Apl. 22585, March 21, 2002.
85. Miyakawa, M.; Sumita, Y; Furuya, K.; Ichikawa, K.; Yamamoto, N.; Hanada, K.; Amano, S.; Nejishima, H. Preparation of Bicyclic Tetrabydroquinoline Derivatives as Androgen Receptor Agonists. World Pat. Apl. 816, Dec 31, 2003.
86. Miyakawa, M.; Oguro, Nao; Hanada, K.; Furuya, K.; Yamamoto, N. Preparation of Novel Tetrahydroquinoline Derivatives as Androgen Receptor Agonists. World Pat. Apl. 13104, Feb 12, 2004.
87. Shiraishi, M.; Hara, T.; Kusaka, M.; Kanzaki, N.; Yamamoto, S.; Miyawaki, T. Preparation of Heterocyclic Moiety-Containing Fused Benzene Derivatives as Androgen Receptor Modulators. World Pat. Apl. 16576, Feb 26, 2004.
88. Cadilla, R.; Larkin, A. L.; Stewart, E. L.; Trump, R. P.; Turnbull, P. S. Preparation of Substituted 1-Naphthalenamines as Modulators of Androgen, Glucocorticoid, Mineralocorticoid, and Progesterone Receptors. World Pat. Apl. 110978, Dec 23, 2004.
89. Blanc, J. E.; Cadilla, R.; Cowan, D. J.; Kaldor, L; Larkin, A. L.; Stewart, E. L.; Turnbull, P. S.; Trump, R. P. Preparation of Substituted Anilines as Androgen Receptor Modulators. World Pat. Apl. 795, Jan 6, 2005.
90. Hu, L.; Du, D. Y.; Lei, H.; Yue, W. Preparation of 5-Cyano-2-amino pyridines as Androgen Receptor Modulators for Treating Various Diseases. World Pat. Apl. 49574, June 2, 2005.
91. Jernstedt, H.; Garg, N.; Gustavsson, A.; Gillner, M.; Garcia Collazo, A.; Koch, E. Preparation of [(phenyl/pyridinyl)amino]alkanols and Related Compounds as Androgen Receptor Modulators with Therapeutic Uses. World Pat. Apl. 42464, May 12, 2005.
92. Kim, Y.; Spencer, K. L.; Hanney, B.; Duggan, M. E. Preparation of Carbonylamino-benzimidazoles as Selective Androgen Receptor Modulators. World Pat Apl. 41277, May 21, 2004.
93. Kim, Y. 29th National Medicinal Chemistry Symposium, Madison, WI, US, June 27-July 1, 2004.
94. Hermkens, P. H. H.; Stock, H. T.; Teerhuis, N. M.; Lommerse, J. P. M.; Van der Louw, J. A Preparation of Indole Derivatives Useful in the Treatment of Androgen-Receptor Related Diseases. World Pat. Apl. 41782, May 21, 2004.
95. Tolman, R. L.; Sahoo, S. P.; Bakshi, R. K.; Gratale, D.; Patel, G.; Patel, S.; Toney, J.; Chang, B.; Harris, G. S. 4-Methyl-3-oxo-4-aza-5α-androst-1 -ene-17β-N-aryl-carboxamides: an Approach to Combined Androgen Blockade [5α-reductase Inhibition with Androgen Receptor Binding in vitro]. J. Ster. Biochem. Mol. Biol. 997, 60, 303-309.
96. Hutchinson, J. H.; Breslin., M. J.; Halczenko, W.; Duggan, M. E.; Harada, S.; Schmidt, A.; Towler, D.; Sahoo, S. P.; Rodan, G. A. Androgen Receptor Modulators and Methods of Use Thereof. World Pat. Apl. 11302, Feb 13, 2003.
97. Meissner, R. S.; Perkins, J. J. Preparation of Fluorinated 4-Aza-androstan-3-one-17β -carboxamide Derivatives as Androgen Receptor Modulators. World Pat Apl. 77919, Sep 25, 2003.
98. Wang, J.; McVean, C. A. Synthesis and Uses of 4-azaSteroid Derivatives as Selective Androgen Receptor Modulators (SARMs). World Pat. Apl. 92588, Nov 13, 2003.
99. Dankulich, W. P.; Kaufman, M. L.; Meissner, R. S.; Mitchell, H. J. Preparation of 3-oxo-4-aza-5α-androst-1-ene-17β-acetamide Derivatives as Androgen Receptor Modulators. World Pat. Apl. 5380, Jan 20, 2005.
100. Dankulich, W. P.; Kaufman, M. L.; Meissner, R. S.; Mitchell, H. J. Preparation of 3-oxo-4-aza-5 α-androst-1-ene-17β-acetamide Derivatives as Androgen Receptor Modulators. World Pat. Apl. 5606, Jan 20, 2005.
101. Dankulich, W. P.; Meissner, R. S.; Mitchell, H. J. Preparation of 17-Acetamido-4-azasteroid Derivatives as Tissue Selective Androgen Receptor Modulators. World Pat. Apl. 9949, Feb 3, 2005.
102. Dankulich, W. P.; Meissner, R. S.; Mitchell, H. J. 17-Acetamido-4-azasteroid Derivatives as Androgen Receptor Modulators for the Treatment of Related Diseases. World Pat. Apl. 4807, Jan 20, 2005.
103. Meissner, R. S.; Perkins, J. J. Identification and Synthesis of Androgen Receptor Modulators and Therapeutic Uses Thereof. World Pat. Apl. 874, Nov 25, 2004.
104. Dankulich, W. P.; Mitchell, H. J. Preparation of 21-Heterocyclic-4-azasteroid Derivatives as Selective Androgen Receptor Modulators. World Pat. Apl. 44988, May 19, 2005.
105. Meissner, R. S.; Mitchell, H. J. Preparation of 17β-Heterocyclic-3-oxo-4-aza-5α-androst-1-ene Derivatives as Androgen Receptor Modulators. World Pat. Apl. 25579, March 24, 2005.
106. Kaufman, M. L.; Meissner, R. S.; Mitchell, H. J. Preparation of 17-Heterocyclic-4-aza-5α-androst-1-en-3-one Derivatives for their Use as Modulators of the Androgen Receptor in a Tissue Selective Manner. World Pat. Apl. 25572, March 24, 2005.
107. Zitzmann, M.; Nieschlag, E. Hormone Replacement in Male Hypogonadism. Mol. Cell. Endo. 2000, 161, 73-88.
108. Wang, C.; Cunningham, G.; Dobs, A.; Iranmanesh, A.; Matsumoto, A. M.; Synder, P. J.; Weber, T.; Berman, N.; Hull, L.; Swerdloff, R. S. Long-Term Testosterone Gel (Androgel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. J. Clin. Endo. Met. 2004, 89, 2085-2098.
109. Anonymous, Centers for Disease Control and Prevention (CDC) MMWR Trends in Aging--United States and Worldwide Morb. Mortality Wkly. Rep. 2003, 52, 101-4, 106.
110. Hijazi, R. A.; Cunningham, G. R. Andropause: is Androgen Replacement Therapy Indicated for the Aging Male? Ann. Rev. Med. 2005, 56, 117-137.
111. Asthana, S.; Bhasin, S.; Butler, R. N.; Fillit, H.; Finkelstein, J.; Harman, S. M.; Holstein, L.; Korenman, S. G.; Matsumoto, A. M.; Morley, J. E.; Tsitouras, P.; Urban, R. Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause. J. Ger., Series A: Biol. Sci. Med. Sci. 2004, 59, 461-465.
112. Cunningham, G R; Tindall, D. J.; Lobl, T. J.; Campbell, J. A.; Means, A. R. Steroid Structural Requirements for High Affinity Binding to Human Sex Steroid Binding Protein (SBP). Steroids 1981, 38, 243-62.
113. Morley, J. Androgens and Aging. Maturitas 2001, 38, 61-73.
114. Tenover, J. L. Testosterrine replacement therapy in older adult man. Int. J. Andrology 1999, 22, 300-306.
115. Lynch, G. S. Emerging Drugs for Sarcopenia: Age-Related Muscle Wasting. Exp. Opin. Emerg. Drugs 2004, 9, 345-361.
116. Doherty, T. J. Aging and Sarcopenia. J. App. Phys. 2003, 95, 1717-1727.
117. Janssen, I.; Shepard, D. S.; Katzmarzyk, P. T.; Roubenoff, R. The Healthcare Costs of Sarcopenia in the United States. JAGS 2003, 80-85.
118. Baumgartner, R. N.; Waters, D. L.; Gallagher, D.; Morley. J. E.; Garry, P. J. Predictors of Skeletal Muscle Mass in Elderly Men and Women. Mech. Ageing Develop. 1999, 107, 123-36.
119. Bhasin, S. Testosterone Supplementation for Aging-Associated Sarcopenia. J. Gerontol. A Biol. Sci. Med. Sci. 2003, 58, 1002-1008.
120. Ferrando, A. A.; Sheffield-Moore, M.; Yeckel, C.W.; Gilkison, C.; Jiang, J.; Achacosa, A.; Lieberman, S. A.; Tipton, K.; Wolfe, R. R.; Urban, R. J. Testosterone Administration to Older Men Improves Muscle Function: Molecular and Physiological Mechanisms. Am. J. Phys. Endo. Met. 2002, 282, E601-E607.
121. Brodsky, I.; Balagopal, P.; Nair, K. Effects of Testosterone Replacement on Muscle Mass and Muscle Protein Synthesis in Hypogonadal men - a Clinical Research Center Study. J. Clin. Endocrinol. Metab. 1996, 81, 3469-3475.
122. Singh, R.; Artaza, J, N.; Taylor, W. E.; Gonzalez-Cadavid, N. F.; Bhasin, S. Androgens Stimulate Myogenic Differentiation and Inhibit Adipogenesis in C3H 10T1/2 Pluripotent Cells Through an Androgen Receptor-Mediated Pathway. Endocrinology 2003, 144, 5081-5088.
123. Hershberger, L.G., Shipley, E., Meyer, R., 1953. Myotrophic Activity of 19-Nortestosterone and Other Steriods Determined by Modified Levator Ani Muscle Method. Myotrophic Activity of Androgens, 175-180.
124. Monks, D. A.; O'Bryant, E. L.; Jordan, C. L. Androgen Receptor Immunoreactivity in Skeletal Muscle: Enrichment at the Neuromuscular Junction. J. Comp. Neur., 2004, 473, 59-72.
125. Gao, W.; Reiser, P. J.; Coss, C. C.; Phelps, M. A.; Kearbey, J. D.; Miller, D. D.; Dalton, J. T. Selective Androgen Receptor Modulator (SARM) Treatment Irnproves Muscle Strength and Body Composition, and Prevents Bone Loss in Orchidectomized Rats Endocrinology, Rapid Electronic Publication first published on Aug 11, 2005.
126. Notelovitz, M. Androgen Effects on Bone and Muscle. Fertil. Steril. 2002, 77, S34-S41.
127. Vanderschueren, D.; Vandenput, L. Androgens and Osteoporosis. Andrologia 2000, 32, 125-30.
128. Smith, M. R. Osteoporosis and Other Adverse Body Composition Changes during Androgen Deprivation Therapy for Prostate Cancer. Cancer and Meta. Rev. 2002, 21, 159-166.
129. Leifke, E.; Korner, H. C.; Link, T. M.; Behre, H. M.; Peters, P. E.; Nieschlag, E. Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men. Eur. J. Endocrinol. 1998, 138, 51-58.
130. Schubert, M.; Bullmann, C.; Minnemann, T.; Reiners, C.; Krone, W.; Jockenhoevel, F. Osteoporosis in Male Hypogonadism: Responses to Androgen Substitution Differ Among Men with Primary and Secondary Hypogonadism. Horm. Res. 2003, 60, 21-28.
131. Rosen, J. and Negro-Vilar, A. Novel, Non-Steroidal, Selective Androgen Receptor Modulators (SARMs) with Anabolic Activity in Bone and Muscle and Improved Safety Profile. J. Musc. Neur. Interact. 2002, 2, 222-224.
132. Kearbey, J. D.; Gao, W.; Miller, D. D.; and Dalton, J. T. Selective Androgen Receptor Modulators Inhibit Bone Resorption in Rats. Pharm. Sci. 2003, 5, R61-1167.
133. Kirby, R. S. The Natural History of Benign Prostatic Hyperplasia: What Have we Learned in the Last Decade? Urology 2000, 56, 3-6.
134. Andriole, G.; Bruchovsky, N.; Chung, L. W. K.; Matsumoto, A. M.; Rittmaster, R.; Roehrborn, C.; Russell, D.; Tindall, D. The Scientific Rationale for 5α-Reductase Inhibitors in the Treatment of Benign Prostatic Hyperplasia. J. Urol. 2004, 172, 1399-1403.
135. Djavan, B.; Barkin, J. Novel Therapeutic Strategies for Managing BPH Progression. Eur. Urol. Suppl. 2003, 2, 20-26.
136. Gao, W.; Kearbey, J. D.; Nair, V. A.; Chung, K.; Parlow, A. F.; Miller, D. D.; Dalton, J. T. Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5α-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia. Endocrinology 2004, 145, 5420-5428.
137. Contraceptive efficacy of Testosterone-Induced Azoospermia, in Normal Men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Lancet 1990, 336, 955-959.
138. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive Efficacy of Testosterone-Induced Azoospermia and Oligozoospermia in Normal Men. Fertil. Steril. 1996, 65, 821-829.
139. Wang, C.; Swerdloff, R. S. Male Hormonal Contraception. Am. J. Obstet. Gynecol. 2004, 190, S60-S68.
140. Wang, C.; Swerdloff, R. S. Male Contraception in the 21st Century. Endocr. Updates 1999, 5, 303-319.
141. Sharpe, R. M.; Donachie, K.; Cooper, I.; Re-evaluation of the Intratesticular Level of Testosterone Required for Quantitative Maintenance of Spermatogenesis in the Rat. J. Endo. 1988, 117, 19-26.
142. Chen, J.; Hwang, D. J.; Bohl, C. E.; Miller, D. D.; Dalton, J. T. A Selective Androgen Receptor Modulator for Hormonal Male Contraception. J. Pharmacol. Exp. Ther. 2005, 312, 546-553.
143. Collins, L. L.; Lee, H. -J.; Chen, Y. -T.; Chang, M.; Hsu, H. -Y.; Yeh, S.; Chang, C. The Androgen Receptor in Spermatogenesis. Cytogenet Genome Res. 2003, 103, 299-301.
144. Laumann E. O.; Paik A.; Rosen R. C. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA 1999, 281, 537-44.
145. Buena, F.; Swerdloff, R. S.; Steiner, B. S.; Lutchmansingh, P.; Peterson, M. A.; Pandian M. R.; Galmarini, M.; Bhasin, S. Sexual Function Does Not Change When Serum Testosterone Levels are Pharmacologically Varied Within the Normal Male Range. Fertil. Steril. 1993, 59, 1118-23.
146. Ansong, K. S.; Punwaney, R. B. An Assessment of the Clinical Relevance of Serum Testosterone Level Determination in the Evaluation of Men with Low Sexual Drive. J. Urol. 1999, 162, 719-721.
147. Davidson, J. M.; Chen, J. J.; Crapo, L.; Gray, G. D.; Greenleaf, W. J.; Catania, J. A. Hormonal Changes and Sexual Function in Aging Men. J. Clin. Endo. Met. 1983, 57, 71-7.
148. Morley, J. E.; Perry, H. M. 3rd Andropause: an Old Concept in New Clothing. Clin. Geriatric Med. 2003, 19, 507-28.
149. Hajjar, R. R.; Kaiser, F. E.; Morley, J. E. Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: a Retrospective Analysis. J. Clin. Endo. Met. 1997, 82, 3793-3796.
150. Morales, A.; Johnston, B.; Heaton, J. P. W.; Lundie, M. Testosterone Supplementation for Hypogonadal Impotence: Assessment of Biochemical Measures and Therapeutic Outcomes. J. Urol. 1997, 157, 849-854.
151. Johannes, C. B.; Araujo, A. B.; Feldman, H. A.; Derby, C. A.; Kleinman, K. P.; McKinlay, J. B. Incidence of Erectile Dysfunction in Men 40 to 69 Years Old: Longitudinal Results from the Massachusetts Male Aging Study. J. Urol. 2000, 163, 460-3.
152. Kaiser F. E. Erectile Dysfunction in the Aging Man. Med. Clin. North Am 1999, 83, 1267-78.
153. Carani, C.; Bancroft, J.; Granata, A.; Del Rio, G.; Marrama, P. Testosterone and Erectile Function, Nocturnal Penile Tumescence and Rigidity, and Erectile Response to Visual Erotic Stimuli in Hypogonadal and Eugonadal Men. Psychoneuroendocrinology 1992, 17, 647-54.
154. Ahn, H. S.; Park, C. M.; Lee, S. W. The Clinical Relevance of Sex Hormone Levels and Sexual Activity in the Ageing Male. BJU International 2002, 89, 526-530.
155. Cunningham, G. R; Hirshkowitz, M; Korenman, S. G; Karacan, I. Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men. J. Clin. Endo. Met. 1990, 70, 792-7.
156. Rhoden, E. L.; Teloken, C.; Sogari, P. R.; Souto, C. A. V. The Relationship of Serum Testosterone to Erectile Function in Normal Aging Men. J. Urol. 2002, 167, 1745-1748.
157. Cameron, D. R.; Braunstein, G. D. Androgen Replacement Therapy in Women. Fert. Steril. 2004, 82, 273-289.